Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)
Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in Addition to Paclitaxel and Carboplatin Versus Placebo in Addition to Paclitaxel and Carboplatin in Subjects With Stage IV/Recurrent Non Small Cell Lung Cancer (NSCLC)
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
The primary objective is to compare Overall Survival (OS) of participants with Stage IV/recurrent NSCLC of squamous histology who have been randomized to ipilimumab in addition to paclitaxel and carboplatin versus placebo in addition to paclitaxel and carboplatin, and have received at least one dose of blinded study therapy (ipilimumab or placebo).
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Exclusion Criteria:
Santiago, 7630370, China
Pribram V-Zdabor, 26195, Czechia
Grosshandsdorf, 22927, Germany
Kurashiki-shi, Okayama-ken 7010192, Japan
Kurashiki-shi, Okayama-ken 710-8602, Japan
Hirakata-shi, Osaka 5731191, Japan
Sunto-gun, Shizuoka 411-8777, Japan
Chuo-ku, Tokyo 104-0045, Japan
Ube-shi, Yamaguchi 7550241, Japan
Akashi, Hyogo, 6738558, Japan
Sapporo Hokkaido, 003-080, Japan
Sendai, Miyagi, 980-0873, Japan
Cercado, Peru
Gdansk- Zaspa, 80-462, Poland
St-Peterburg, 198255, Russia
Cheonju-si, North Chungcheong 361-771, South Korea
Benidorm-alicante, 03501, Spain
Kaohsiung County, 83301, Taiwan